Skip to main content
Clinical Trials/NCT02507297
NCT02507297
Completed
Not Applicable

Sleep-Disordered Breathing and PAP in Perinatal Depression

University of Michigan1 site in 1 country29 target enrollmentJanuary 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Sleep-disordered Breathing
Sponsor
University of Michigan
Enrollment
29
Locations
1
Primary Endpoint
Change in Hamilton Rating Scale for Depression (HRSD) Score, Minus the Sleep Item
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The goal of this study is to understand the contribution of sleep-disordered breathing (SDB) to one of the most common and debilitating adverse pregnancy outcomes, perinatal depression. The study is a randomized trial to test the efficacy of positive airway pressure (PAP) on sleep and depression symptoms in perinatal women. Participants will be pregnant women with depression and sleep-disordered breathing. Participants will be randomly assigned to receive either PAP therapy (PAP group) or treatment as usual within obstetrics (TAU group). Mood and sleep assessments will be completed at baseline, after 1 week of enrollment, and monthly thereafter through 12 weeks postpartum. Cortisol will be measured using saliva collection at baseline and again 8 weeks later.

Registry
clinicaltrials.gov
Start Date
January 2016
End Date
April 25, 2020
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Leslie Swanson

Clinical Assistant Professor

University of Michigan

Eligibility Criteria

Inclusion Criteria

  • 20-32 weeks gestation with a single, live fetus
  • meet criteria for major depressive disorder per the Structured Clinical Interview for DSM-V (SCID)
  • respiratory distress index (RDI; includes apneas, hypopneas, and respiratory effort-related arousals)≥5 per ambulatory assessment plus apnea symptoms (snoring, witnessed apnea, daytime sleepiness, sleep disturbance, snort arousals)
  • stable dose (for ≥8 weeks) of a selective serotonin reuptake inhibitor (SSRI) OR free of all antidepressant medications past 4 weeks
  • obstetrics care is at the University of Michigan, and the woman plans on delivering her baby at the University of Michigan

Exclusion Criteria

  • Diagnosis of bipolar disorder, posttraumatic stress disorder, schizophrenia or psychosis, dissociative disorders, eating disorder, obsessive-compulsive disorder, somatic symptom and related disorders, substance use disorder, panic disorder, agoraphobia per DSM-V
  • diagnosis of, or suspicion for, narcolepsy or REM behavior disorder
  • current SDB treatment; medical conditions for which PAP is contraindicated (e.g., pneumothorax, pneumocephalus, recent trauma, recent surgery)
  • evidence of risk for drowsy driving (excessive daytime sleepiness plus history of motor vehicle accident or near miss due to sleepiness, fatigue, or inattention in past 12 months).

Outcomes

Primary Outcomes

Change in Hamilton Rating Scale for Depression (HRSD) Score, Minus the Sleep Item

Time Frame: Baseline to 8 weeks after baseline, and at 12 weeks postpartum

Change in clinician-rated depression severity and symptoms, excluding the items which measure sleep. Total score range: 0-46. Higher scores represent more severe depression.

Secondary Outcomes

  • Change in Epworth Sleepiness Scale (ESS) Score(Baseline to 8 weeks after baseline, and at 12 weeks postpartum)
  • Change in Salivary Cortisol(Baseline to 8 weeks after baseline)
  • Change in Edinburgh Postnatal Depression Scale Score(Baseline to 8 weeks after baseline, and at 12 weeks postpartum)
  • Change in Pittsburgh Sleep Quality Index Score(Baseline to 8 weeks after baseline, and at 12 weeks postpartum)

Study Sites (1)

Loading locations...

Similar Trials